Amanote Research
Register
Sign In
Approaching Resistance to Targeted Inhibition of PI3K in Breast Cancer
doi 10.21236/ada555900
Full Text
Open PDF
Abstract
Available in
full text
Date
October 1, 2011
Authors
Nina Ilic
Publisher
Defense Technical Information Center
Related search
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer
Cancer Discovery
Oncology
Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
Cancer Cell
Cancer Research
Oncology
Cell Biology
mTORC1 Inhibition Is Required for Sensitivity to PI3K P110 Inhibitors in PIK3CA-Mutant Breast Cancer
Science Translational Medicine
Medicine
Interleukin-6 Mediates Resistance to PI3K-pathway–targeted Therapy in Lymphoma
BMC Cancer
Cancer Research
Oncology
Genetics
Vertical Inhibition of the PI3K/Akt/mTOR Pathway Is Synergistic in Breast Cancer
Oncogenesis
Cancer Research
Molecular Biology
Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway
Current Cancer Drug Targets
Cancer Research
Drug Discovery
Oncology
Pharmacology
Targeted Lapatinib Anti-Her2/ErbB2 Therapy Resistance in Breast Cancer: Opportunities to Overcome a Difficult Problem
CXCR4-targeted Therapy in Breast Cancer
The Lancet Oncology
Oncology
Dual Inhibition of PI3K and mTOR Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer
Molecular Cancer Research
Cancer Research
Oncology
Molecular Biology